Evidera
Nicolas KRUCIEN is a Principal Scientist at Evidera since August 2019, previously holding the position of Senior Data Analyst. KRUCIEN served as a Research Fellow in Health Economics at the University of Aberdeen from November 2013 to April 2021, specializing in preferences-elicitation studies and modeling. Prior to this role, a post-doctoral fellowship at Inserm focused on patients' preferences for the treatment of sleep apnea syndrome. KRUCIEN began academic training as a PhD student at the Center for Education and Research in Medicine, Ecology and Sociology, completing a PhD in health economics with a focus on patient preferences in general practice care in France. Educational credentials include a PhD and a Master 2 in Health Economics from Paris-Sud University, a Master's degree in Development Economics from the Institut d'études du développement de la Sorbonne, and a License in Economics from Université de Rouen.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.